Key result
Inhibiting POSTN in prostate cancer cells significantly alleviated bone metastasis in vivo, and 18F-Alfatide II PET/CT revealed high intake of the integrin αvβ3 probe in metastatic lesions of prostate cancer patients.
Why the study?
Exploring the biological function of periostin in prostate cancer bone metastasis is important given its high expression in prostate cancer metastasized to bone.
Does inhibiting POSTN reduce prostate cancer bone metastasis?
Does inhibiting POSTN reduce prostate cancer bone metastasis?
Targeting periostin in prostate cancer cells and osteoblasts may be a promising therapeutic strategy for prostate cancer bone metastasis.
POSTN inhibition merits exploration in prostate cancer bone metastasis; hypothesis-generating and requires clinical trials before any practice change.
Exploring the biological function of periostin (POSTN) in prostate cancer (PCa) bone metastasis is of importance. It was observed that the expression of POSTN was high in PCa, especially highest in PCa metastasized to bone. In this study, we found that inhibiting POSTN in PCa cells could significantly alleviate PCa bone metastasis in vivo, suggesting POSTN is a promising therapeutic target. Since, due to the secreted expression of POSTN in osteoblasts and PCa, we hypothesized the positive feedback loop between osteoblasts and PCa mediated by POSTN in PCa bone metastasis. The in vitro experiments demonstrated that osteoblast-derived POSTN promoted PCa cell proliferation and invasion and PCa cell-derived POSTN promotes proliferation of osteoblasts. Furthermore, we found that POSTN regulated PCa and osteoblast function through integrin receptors. Finally, 18F-Alfatide II was used as the molecule probe of integrin αvβ3 in PET-CT, revealing high intake in metastatic lesions. Our findings together indicate that targeting POSTN in PCa cells as well as in the osteoblastic may be an effective treatment for PCa bone metastasis.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2022) studied Prostate cancer (n=21). 18F-Alfatide II PET/CT imaging was evaluated on Intake degree of bone lesions on 18F-Alfatide II PET/CT. Inhibiting POSTN in prostate cancer cells significantly alleviated bone metastasis in vivo, and 18F-Alfatide II PET/CT revealed high intake of the integrin αvβ3 probe in metastatic lesions of prostate cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: